LockdownV1, Main, Corpus, bibRecord, 001E91

Prescription rates of cardiovascular and diabetes therapies prior to and during the COVID-19 lockdown in Germany.

Identifieur interne : 001E91 ( Main/Corpus ); précédent : 001E90; suivant : 001E92

Prescription rates of cardiovascular and diabetes therapies prior to and during the COVID-19 lockdown in Germany.

Auteurs : Karel Kostev ; Sachin Kumar ; Marcel Konrad ; Jens Bohlken

Source :

International journal of clinical pharmacology and therapeutics [ 0946-1965 ] ; 2020.

RBID : pubmed:32729826

English descriptors

KwdEn :
- Antihypertensive Agents (therapeutic use), Betacoronavirus (MeSH), COVID-19 (MeSH), Cardiovascular Diseases (prevention & control), Coronavirus Infections (epidemiology), Cross-Sectional Studies (MeSH), Diabetes Mellitus (drug therapy), Drug Prescriptions (statistics & numerical data), Germany (epidemiology), Humans (MeSH), Hypoglycemic Agents (therapeutic use), Pandemics (MeSH), Pneumonia, Viral (epidemiology), SARS-CoV-2 (MeSH).
MESH :
- chemical , therapeutic use : Antihypertensive Agents, Hypoglycemic Agents.
- geographic , epidemiology : Germany.
- drug therapy : Diabetes Mellitus.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- prevention & control : Cardiovascular Diseases.
- statistics & numerical data : Drug Prescriptions.
- Betacoronavirus, COVID-19, Cross-Sectional Studies, Humans, Pandemics, SARS-CoV-2.

Abstract

AIMS

The aim of this study was to examine the development in the number of patients receiving cardiovascular or antidiabetic medications from pharmacies in the first quarter of 2020.

METHODS

This cross-sectional study was based on the data from more than 10 million patients in the IMS longitudinal prescription (LRx) database. The outcome of this study was the development in the number of patients receiving cardiovascular or diabetic medications from pharmacies in January, February, and March 2020, compared to January, February, and March 2019.

RESULTS

From March 2019 to March 2020, there was a 39% increase in angiotensin II antagonist prescriptions, a 33% increase in lipid-lowering drug prescriptions, a 32% increase in calcium channel blocker (CCB) prescriptions, a 30% increase in beta blocker prescriptions, a 27% increase in angiotensin-converting enzyme (ACE) inhibitor, vitamin k antagonist (VKA), and oral antidiabetic prescriptions, a 24% increase in diuretic prescriptions, and an 18% increase in insulin prescriptions. The largest increase was found in the age group of 18 - 40 years (e.g., 57% for VKA, 52% for CCB and angiotensin II antagonists), and the smallest increase occurred in the age group over 80 years (for example, 10% for VKA, 9% for oral antidiabetics, and 3% for insulins).

CONCLUSION

The number of patients receiving their drugs from pharmacies was significantly higher in March 2020 than in March 2019, which is an indication of good therapy adherence. Additional studies are needed to examine adherence during the COVID-19 pandemic and possible age differences in adherence.

DOI: 10.5414/CP203849
PubMed: 32729826

Links to Exploration step

pubmed:32729826

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prescription rates of cardiovascular and diabetes therapies prior to and during the COVID-19 lockdown in Germany.</title>
<author><name sortKey="Kostev, Karel" sort="Kostev, Karel" uniqKey="Kostev K" first="Karel" last="Kostev">Karel Kostev</name>
</author>
<author><name sortKey="Kumar, Sachin" sort="Kumar, Sachin" uniqKey="Kumar S" first="Sachin" last="Kumar">Sachin Kumar</name>
</author>
<author><name sortKey="Konrad, Marcel" sort="Konrad, Marcel" uniqKey="Konrad M" first="Marcel" last="Konrad">Marcel Konrad</name>
</author>
<author><name sortKey="Bohlken, Jens" sort="Bohlken, Jens" uniqKey="Bohlken J" first="Jens" last="Bohlken">Jens Bohlken</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32729826</idno>
<idno type="pmid">32729826</idno>
<idno type="doi">10.5414/CP203849</idno>
<idno type="wicri:Area/Main/Corpus">001E91</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001E91</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Prescription rates of cardiovascular and diabetes therapies prior to and during the COVID-19 lockdown in Germany.</title>
<author><name sortKey="Kostev, Karel" sort="Kostev, Karel" uniqKey="Kostev K" first="Karel" last="Kostev">Karel Kostev</name>
</author>
<author><name sortKey="Kumar, Sachin" sort="Kumar, Sachin" uniqKey="Kumar S" first="Sachin" last="Kumar">Sachin Kumar</name>
</author>
<author><name sortKey="Konrad, Marcel" sort="Konrad, Marcel" uniqKey="Konrad M" first="Marcel" last="Konrad">Marcel Konrad</name>
</author>
<author><name sortKey="Bohlken, Jens" sort="Bohlken, Jens" uniqKey="Bohlken J" first="Jens" last="Bohlken">Jens Bohlken</name>
</author>
</analytic>
<series><title level="j">International journal of clinical pharmacology and therapeutics</title>
<idno type="ISSN">0946-1965</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antihypertensive Agents (therapeutic use)</term>
<term>Betacoronavirus (MeSH)</term>
<term>COVID-19 (MeSH)</term>
<term>Cardiovascular Diseases (prevention & control)</term>
<term>Coronavirus Infections (epidemiology)</term>
<term>Cross-Sectional Studies (MeSH)</term>
<term>Diabetes Mellitus (drug therapy)</term>
<term>Drug Prescriptions (statistics & numerical data)</term>
<term>Germany (epidemiology)</term>
<term>Humans (MeSH)</term>
<term>Hypoglycemic Agents (therapeutic use)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (epidemiology)</term>
<term>SARS-CoV-2 (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antihypertensive Agents</term>
<term>Hypoglycemic Agents</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Germany</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Diabetes Mellitus</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Cardiovascular Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Drug Prescriptions</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term>
<term>COVID-19</term>
<term>Cross-Sectional Studies</term>
<term>Humans</term>
<term>Pandemics</term>
<term>SARS-CoV-2</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>AIMS</b>
</p>
<p>The aim of this study was to examine the development in the number of patients receiving cardiovascular or antidiabetic medications from pharmacies in the first quarter of 2020.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>METHODS</b>
</p>
<p>This cross-sectional study was based on the data from more than 10 million patients in the IMS longitudinal prescription (LRx) database. The outcome of this study was the development in the number of patients receiving cardiovascular or diabetic medications from pharmacies in January, February, and March 2020, compared to January, February, and March 2019.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>From March 2019 to March 2020, there was a 39% increase in angiotensin II antagonist prescriptions, a 33% increase in lipid-lowering drug prescriptions, a 32% increase in calcium channel blocker (CCB) prescriptions, a 30% increase in beta blocker prescriptions, a 27% increase in angiotensin-converting enzyme (ACE) inhibitor, vitamin k antagonist (VKA), and oral antidiabetic prescriptions, a 24% increase in diuretic prescriptions, and an 18% increase in insulin prescriptions. The largest increase was found in the age group of 18 - 40 years (e.g., 57% for VKA, 52% for CCB and angiotensin II antagonists), and the smallest increase occurred in the age group over 80 years (for example, 10% for VKA, 9% for oral antidiabetics, and 3% for insulins).</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSION</b>
</p>
<p>The number of patients receiving their drugs from pharmacies was significantly higher in March 2020 than in March 2019, which is an indication of good therapy adherence. Additional studies are needed to examine adherence during the COVID-19 pandemic and possible age differences in adherence.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">32729826</PMID>
<DateCompleted><Year>2020</Year>
<Month>09</Month>
<Day>08</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0946-1965</ISSN>
<JournalIssue CitedMedium="Print"><Volume>58</Volume>
<Issue>9</Issue>
<PubDate><Year>2020</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>International journal of clinical pharmacology and therapeutics</Title>
<ISOAbbreviation>Int J Clin Pharmacol Ther</ISOAbbreviation>
</Journal>
<ArticleTitle>Prescription rates of cardiovascular and diabetes therapies prior to and during the COVID-19 lockdown in Germany.</ArticleTitle>
<Pagination><MedlinePgn>475-481</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.5414/CP203849</ELocationID>
<Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">The aim of this study was to examine the development in the number of patients receiving cardiovascular or antidiabetic medications from pharmacies in the first quarter of 2020.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">This cross-sectional study was based on the data from more than 10 million patients in the IMS longitudinal prescription (LRx) database. The outcome of this study was the development in the number of patients receiving cardiovascular or diabetic medications from pharmacies in January, February, and March 2020, compared to January, February, and March 2019.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">From March 2019 to March 2020, there was a 39% increase in angiotensin II antagonist prescriptions, a 33% increase in lipid-lowering drug prescriptions, a 32% increase in calcium channel blocker (CCB) prescriptions, a 30% increase in beta blocker prescriptions, a 27% increase in angiotensin-converting enzyme (ACE) inhibitor, vitamin k antagonist (VKA), and oral antidiabetic prescriptions, a 24% increase in diuretic prescriptions, and an 18% increase in insulin prescriptions. The largest increase was found in the age group of 18 - 40 years (e.g., 57% for VKA, 52% for CCB and angiotensin II antagonists), and the smallest increase occurred in the age group over 80 years (for example, 10% for VKA, 9% for oral antidiabetics, and 3% for insulins).</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The number of patients receiving their drugs from pharmacies was significantly higher in March 2020 than in March 2019, which is an indication of good therapy adherence. Additional studies are needed to examine adherence during the COVID-19 pandemic and possible age differences in adherence.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kostev</LastName>
<ForeName>Karel</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kumar</LastName>
<ForeName>Sachin</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Konrad</LastName>
<ForeName>Marcel</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Bohlken</LastName>
<ForeName>Jens</ForeName>
<Initials>J</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Germany</Country>
<MedlineTA>Int J Clin Pharmacol Ther</MedlineTA>
<NlmUniqueID>9423309</NlmUniqueID>
<ISSNLinking>0946-1965</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003920" MajorTopicYN="N">Diabetes Mellitus</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011307" MajorTopicYN="N">Drug Prescriptions</DescriptorName>
<QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>08</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>7</Month>
<Day>31</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>9</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>7</Month>
<Day>31</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32729826</ArticleId>
<ArticleId IdType="pii">187020</ArticleId>
<ArticleId IdType="doi">10.5414/CP203849</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/LockdownV1/Data/Main/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E91 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001E91 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    LockdownV1
   |flux=    Main
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:32729826
   |texte=   Prescription rates of cardiovascular and diabetes therapies prior to and during the COVID-19 lockdown in Germany.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i   -Sk "pubmed:32729826" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a LockdownV1

This area was generated with Dilib version V0.6.38.
Data generation: Sun Jan 31 08:28:27 2021. Site generation: Sun Jan 31 08:33:49 2021

	Serveur d'exploration sur le confinement (PubMed)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le confinement (PubMed)

Prescription rates of cardiovascular and diabetes therapies prior to and during the COVID-19 lockdown in Germany.

Prescription rates of cardiovascular and diabetes therapies prior to and during the COVID-19 lockdown in Germany.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki